CORAT Therapeutics GmbH develops COR-101, a fully human neutralizing antibody that targets the SARS-CoV-2 virus to provide immediate antiviral effects for COVID-19 patients. This therapeutic drug is designed to reduce viral load by over 99% in the lungs, offering a treatment option for individuals who are unvaccinated or have not responded adequately to vaccination.
Funding
$42.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DFounders
Product
Problem
Many individuals, including those unvaccinated or with breakthrough infections, require effective treatments to combat SARS-CoV-2 and prevent severe COVID-19 outcomes. Current vaccines may not provide sufficient protection for all, and therapeutic options are needed to reduce viral load and promote recovery in infected patients.
Solution
CORAT Therapeutics develops COR-101, a fully human, recombinant, neutralizing antibody designed to treat COVID-19. COR-101 works by binding to the SARS-CoV-2 virus, preventing it from infecting human cells and reducing the viral burden in infected individuals. The antibody targets various surface molecules of the SARS-CoV-2 virus, including the receptor binding domain (RBD), effectively neutralizing the virus and facilitating its clearance from the bloodstream. COR-101 is designed for both prophylactic use in vulnerable individuals and therapeutic intervention in infected patients, offering immediate antiviral effects.
Target Audience
The primary target audience includes individuals infected with SARS-CoV-2, particularly those who are unvaccinated, have not responded adequately to vaccination, or are at high risk of severe disease progression, as well as healthcare workers and other vulnerable individuals seeking prophylactic protection.
Features
- Fully human monoclonal antibody developed using phage display from human antibody gene libraries.
- Designed to neutralize SARS-CoV-2 by occupying the attachment site of the viral spike protein.
- Demonstrated in preclinical models to reduce virus load in the lung by more than 99%.
- Designed with a safety modification for use in patients with moderate to severe COVID-19.
- Binds to most SARS-CoV-2 variants, including the Delta variant (B.1.617.2).
- GMP-compliant production process.